Measure ID: MIPS 421|Vascular Access|2026 Performance Year

Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal

Percentage of patients in whom a retrievable IVC filter is placed who, within 3 months post-placement, have a documented assessment for the appropriateness of continued filtration, device removal, or the inability to contact the patient with at least two attempts.

ProcessVascular AccessAppropriate Use

Last updated: January 15, 2026

⚙️

Measure Specification

Denominator (Eligible Population)

All patients, regardless of age
ANDPatient procedure during the performance period
ANDIntent for Potential Removal at Time of Placement: G9539
ANDPatient alive 3 Months Post Procedure: G9540
ORPerformance Met: Documented re-assessment for the appropriateness of filter removal within 3 months of placement (G9542)
ORPerformance Met: Documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement (G9543)
ORPerformance Not Met: Patients that do not have the filter removed, documented re-assessment for the appropriateness of filter removal, or documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement (G9544)

Denominator Exclusions

None

Numerator

Number of patients that have appropriate IVC filter follow-up.

Submission Codes (QDCs)

✓ Performance Met
G9541Filter removed within 3 months of placement
G9542Documented re-assessment for the appropriateness of filter removal within 3 months of placement
G9543Documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement
✗ Performance Not Met
G9544Patients that do not have the filter removed, documented re-assessment for the appropriateness of filter removal, or documentation of at least two attempts to reach the patient to arrange a clinical re-assessment for the appropriateness of filter removal within 3 months of placement

Denominator Exceptions

None — this measure has no denominator exceptions.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

%Benchmarks vary by collection type
💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.
VBCA Insights

💡Why This Measure Matters

Retrievable IVC filters are placed temporarily to prevent blood clots, but they need to be removed once they're no longer needed because they carry long-term risks. This measure ensures you're documenting a reassessment within 3 months of placement and either removing the filter or clearly explaining why it must stay. Set up a system to flag these patients for follow-up—it's easy to lose track of temporary devices, and unintended permanent placement is a patient safety issue.

📖Clinical Rationale

There is a need for increased physician awareness of the potential harms of inappropriate continued inferior vena cava filtration in patients with retrievable filters. Patients with retrievable inferior filters need to be carefully followed for re- assessment of the clinical need for continued inferior vena cava filtration, leading to removal of such devices when clinically appropriate.

Complexities of our healthcare system, notably the use of inferior vena cava filters in the in-patient setting, followed by transfer of care to physicians in the outpatient setting highlight the importance of patient follow-up for physicians placing retrievable inferior vena cava filters.

📝Clinical Recommendations

Retrievable filter complications have been increasingly noted in the FDA MAUDE database and in the literature. Retrievable filters were designed differently than permanent filters and the incidence of device related complications with long term insertions are higher than in comparison to permanent filters. The FDA has recommended that physicians that place these filters carefully monitor these patients and remove these filters at the earliest possible time.

Dedicated follow-up for IVC filters has led to an increase in retrieval rate. The FDA recommends that all physicians placing IVC Filters and those responsible for ongoing care of these patients remove the filter as soon as protection from pulmonary embolism is no longer needed. The FDA encourages follow-up on patients to consider risks and benefits of filter removal (1).

📋Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this procedure measure is submitted each time a procedure is performed during the performance period. There is no diagnosis associated with this measure. Include only patients that have IVC filter placement through September 30 of the performance period.

This will allow the evaluation of at least 90 days of IVC filter removal within the performance period.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →
© 2025 Society of Interventional Radiology.